Lung Cancer

Combination Cisplatin, Etoposide and Sunitinib for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study [CALGB 30504]  Accrual to this protocol is temporarily suspended.

Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Memorial Hospital
(708) 579-3418
Contact: Terri Crestani, MPH

A Phase II Study of Dasatinib (NSC #732517, IND #73969) in Patients with Chemo-
sensitive Relapsed Small Cell Lung Cancer [CALGB 30602]

Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH

Interferon Alpha (NSC #377523) plus 13-Cis-Retinoic Acid Modulation of Bcl-2 plus Paclitaxel for Recurrent Small Cell Lung Cancer (SCLC) [ECOG 6501]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.

Other

A Phase II Randomized Study of OSI-774 (erlotinib) (NSC #718781; IND #63,383) with or without Carboplatin/Paclitaxel in Patients with Previously-Untreated Adenocarcinoma of the Lung who Never Smoked or were Former Light Smokers [CALGB 30406]

Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH

Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men [SWOG 0424]

Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH

Non-Small Cell Lung Cancer

A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Sunitinib(NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer [CALGB 30607]

Principal Investigator:
James Hannigan, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely-Resected Stage 1B) (>4cm) to IIIA Non-Small Cell Lung Cancer (NSCLC) [ECOG 1505]

Principal Investigator:
Elyse Schneiderman, M.D.
Adventist Hinsdale Hospital
(630) 654-1790
Contact: Jan Wilson, R.N.

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely-Resected Stage 1B) (>4cm) to IIIA Non-Small Cell Lung Cancer (NSCLC) [ECOG 1505]

Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH

Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men [SWOG 0424 CTSU]

Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH